BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Onyx Pharmaceuticals and Bayer Drug Trial Fails]]>http://www.bloggingstocks.com/2010/06/14/Bayer-onyx-pharmaceuticals-trial-fails/http://www.bloggingstocks.com/2010/06/14/Bayer-onyx-pharmaceuticals-trial-fails/http://www.bloggingstocks.com/2010/06/14/Bayer-onyx-pharmaceuticals-trial-fails/#commentsFiled under:

Bayer and Onyx Pharmaceuticals (ONXX) announced Monday morning that a Phase III study of lung cancer treatment Nexavar did not meet its primary endpoint -- improving overall survival. The two pharmaceutical firms said they were "disappointed" with the failure of the trial and that they will evaluate the findings to see if the data may have any impact on other Nexavar trials.

This trial was measuring Nexavar plus the standard treatment chemotherapy drugs against the chemo drugs alone in patients with newly diagnosed non-small cell lung cancer. Non-small cell lung cancer comprises roughly 85% to 90% of diagnosed lung cancers. Nexavar is already used to treat kidney and liver cancer.

Continue reading Onyx Pharmaceuticals and Bayer Drug Trial Fails

Onyx Pharmaceuticals and Bayer Drug Trial Fails originally appeared on BloggingStocks on Mon, 14 Jun 2010 09:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>BayerBayer AGdrug trialsinthenewsNexavarONXXOnyx PharmaceuticalsMon, 14 Jun 2010 09:30:00 EST<![CDATA[Option update: Onyx Pharma volatility elevated into 20% pre-open sell off]]>http://www.bloggingstocks.com/2008/02/19/option-update-onyx-pharma-volatility-elevated-into-20-pre-open/http://www.bloggingstocks.com/2008/02/19/option-update-onyx-pharma-volatility-elevated-into-20-pre-open/http://www.bloggingstocks.com/2008/02/19/option-update-onyx-pharma-volatility-elevated-into-20-pre-open/#commentsFiled under:

Onyx Pharma (NASDAQ: ONXX) is recently is down $9.23 to $35.70 in pre-open trading.

ONXX and its partner Bayer halted Phase 3 trials of Nexavar and after the company reported a larger than expected Q4 loss.

ONXX overall option implied volatility of 63 is above its 26-week average of 57 according to Track Data, suggesting larger price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Option update: Onyx Pharma volatility elevated into 20% pre-open sell off originally appeared on BloggingStocks on Tue, 19 Feb 2008 09:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>BayerinthenewsNexavaronxxonyx pharmaOnyxPharmaoption implied volatilityOptionImpliedVolatilityTue, 19 Feb 2008 09:30:00 EST